Introduction {#sec1_1}
============

Originally described in 1995, primary effusion lymphoma (PEL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) universally associated with human herpes virus-8 (HHV-8) that involves body cavities and causes serous effusions without detectable masses or lymphadenopathy according to the World Health Organization (WHO) classification of tumors about hematopoietic and lymphoid tissue \[[@B1], [@B2], [@B3], [@B4]\]. It occurs mainly in immunocompromised patients infected with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) \[[@B2], [@B4], [@B5]\]. On the other hand, in Japan, many cases of DLBCL with lymphomatous effusions on serosal surfaces and no detectable mass lesion like PEL have been reported. These cases were not regarded as cases of PEL but as a new entity, "PEL-like lymphoma (PEL-LL)" \[[@B6]\].

Herein, we report a case of an elderly female patient with DLBCL with bilateral pleural effusion and massive pericardial effusion. The type of DLBCL was difficult to determine because clinical features and several findings of examinations resembled PEL or PEL-LL; however, the patient\'s hematological findings could not be diagnosed as both.

Case Report {#sec1_2}
===========

A 93-year-old female was transferred to the emergency ward of our hospital due to disturbance of consciousness and hypotension. Her medical history included gastric tube feeding due to cerebral infarction and disuse syndrome, complicated by hypertension, atrial fibrillation, chronic renal insufficiency, and constipation. She was under treatment with antiplatelet, antihypertensive, and cathartic medications. She had been bedridden for a number of years and had received regular medical and nursing care at home. When the ambulance call to render medical assistance arrived at her home, she had fully recovered her consciousness, her blood pressure was within normal limits, and she did not complain of B symptoms.

In the emergency room, she presented with mild disturbance of consciousness (Japan coma scale 1), irregular pulse rate, and mild pitting edema to bilateral lower legs. She was negative for lymphadenopathy and hepatosplenomegaly. Urinalysis showed asymptomatic bacteriuria, and routine blood tests showed normocytic anemia, hypoalbuminemia, and several chemical data such as C-reactive protein, lactate dehydrogenase, creatinine, blood urea nitrogen, potassium, ferritin, and soluble interleukin-2 receptor were elevated. Electrocardiogram showed atrial fibrillation, and carotid ultrasonography showed moderate arteriosclerosis. Computed tomography of her head, neck, chest, and abdomen showed multiple lacunar infarction, bilateral pleural effusion, pericardial effusion, and bilateral renal atrophy. There was, however, no evidence of tumor mass, lymph node enlargement, or hepatosplenomegaly on computed tomography. Echocardiography showed massive pericardial effusion. Examination ruled out heart failure, infectious disease, and collagen disease. The patient was admitted to our hospital for intensive examination and treatment. Pericardial drainage was not performed because she was not in cardiac tamponade and, in addition to this, there was apprehension about iatrogenic damage to her heart. Pleural effusion was revealed to be exudative and seemed to be the cause of the patient\'s dyspnea. Microscopic observation of pleural effusion showed hemophagocytosis as well as proliferation of atypical lymphoid-like blast cells, which were positive for cluster of differentiation (CD) 19, CD20, and CD25 (Fig. [1a, b](#F1){ref-type="fig"}). Flow cytometry of the cells in pleural effusion was negative for monoclonality in B-lymphocyte fraction. Additionally, evidence of HIV and/or EBV infection was not detected, and cytogenetic analysis for HHV-8 and lymph node biopsy could not be performed. From the above, we suspected malignant lymphoma such as PEL-LL; however, we were unable to arrive at a conclusive diagnosis. Bone marrow examination revealed the same atypical lymphoid-like cells seen in pleural effusion; however, there was no evidence of neoplastic proliferation tumorous growth (Fig. [2a, b](#F2){ref-type="fig"}). Cell surface antigen analysis of bone marrow cells revealed strong deviation to gamma-chain side in B-lymphocyte fraction, which we suspected was due to neoplastic proliferation tumorous growth (Fig. [2c](#F2){ref-type="fig"}). Furthermore, because the CD20-positive cell rate was high (approx. 70%), we suspected that the tumor cells were CD20-positive. Chromosomal abnormality was not confirmed. The above findings prompted a diagnosis of DLBCL with bone marrow invasion rather than PEL-LL.

Considering the patient\'s age and the side effects of chemotherapy, we administered 8 cycles of chemotherapy with rituximab 375 mg/m^2^ once per week (Fig. [2](#F2){ref-type="fig"}). Fortunately, her vital signs improved immediately and her symptoms gradually resolved. Furthermore, we confirmed that her pericardial effusion significantly decreased after 4 cycles of chemotherapy and disappeared after 8 cycles. Judged to have been in complete remission, she was discharged from the hospital on day 109 of hospitalization (Fig. [3](#F3){ref-type="fig"}). At the 28-month follow-up, the patient remained free of recurrence.

Discussion {#sec1_3}
==========

The most significant lesson learned from our experience with the present case is our initial diagnosis of PEL-LL. Actually, the present case had many clinical features mimicking PEL-LL. She suffered from circulatory failure and had massive pericardial fluid with pleural effusion, in which many atypical lymphoid cells were detected. It was our inability to confirm monoclonal B-cell tumor after more careful examination that prompted us to change our diagnosis to DLBCL.

Here, a fundamental question arises as to whether it is possible to diagnose B-cell lymphoma on first observation. The WHO classification proposes that PEL be universally defined as an immune deficiency-related lymphoma and associated with HHV-8 infection \[[@B7]\]. Therefore, our patient\'s condition could not have been diagnosed as PEL because she had no immunodeficiency. In addition, PEL-LL was not a definite disease unit in the 2016 revision of the WHO classification of lymphoid neoplasms. This should, therefore, be discussed at greater length \[[@B8]\]. HCV, iatrogenic immunodeficiency, alcoholism, liver cirrhosis, cancer, and advanced age have been reported as possible reasons for PEL-LL. PEL-LL affects elderly patients (median age, 74 years) and patients with volume overload such as those with liver cirrhosis (12%) or congestive heart failure (5.5%); and PEL-LL patients have a greater number of CD20-positive cells (86%) than PEL patients. Additionally, patients with ascites have a higher incidence of HCV infection (39%) than pericardial effusion (7%) or pleural effusion (9%) \[[@B2], [@B6], [@B9], [@B10], [@B11]\]. Cytologically, PEL-LL cells resemble the large atypical cells of DLBCL, and their neoplastic cells show immunoreactivity for pan-B-cell markers such as CD19, CD20, and CD79a; the lymphoma cells express pan-B-cell antigens in 86.7%, and CD20 is expressed in 71.1% of the cases. On the other hand, the neoplastic cells in PEL usually lack such immunoreactivity \[[@B3], [@B5], [@B6], [@B9]\]. The features of our case are close to previously reported cases of PEL-LL in terms of age, pleural and pericardial effusions, lack of tumor mass, and detected atypical lymphoid blasts in the effusion (Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}). Due to the fact that monoclonal lymphoma cells had not been detected in pleural effusion, pericardial and pleural effusion was thought to be associated with lymphoma, especially PEL-LL, and not DLBCL. In addition, the patient maintained complete remission after rituximab monotherapy without recurrence of pericardial or pleural effusion, and without treatment for heart failure or other condition for an extended period, which is also generally consistent with the clinical course of PEL-LL. Even if the disease had been DLBCL, this case is remarkable because monotherapy with rituximab is a suboptimal and noncurative treatment for DLBCL in elderly patients. However, it is quite difficult to diagnose from nonspecific symptoms and laboratory abnormalities. Considering Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, the presence of neoplastic change in bone marrow, absence of monoclonal B cell in pleural effusion by flow cytometry, and chromosomal abnormality are inconsistent with the characteristics of PEL-LL. Hence, the diagnosis may be PEL-LL-like DLBCL rather than PEL-LL. Strictly speaking, a diagnosis of DLBCL or intravascular lymphoma can only be made in a broad sense. From this point of view, massive pericardial and pleural effusion including atypical lymphoid cells in the present case are quite interesting.

In conclusion, we experienced an elderly patient with DLBCL mimicking PEL-LL. This case suggests the need for a careful and detailed examination from the first observation when encountering patients with pericardial or pleural effusion and inclusion of hematological malignancy in the differential diagnosis.
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![Images of cytodiagnosis: pleural fluid. **a** Atypical cell is confirmed (green arrow). May-Giemsa staining. ×1, 000. **b** Atypical cell (green arrow) and hemophagocytosis (red arrows) are confirmed. May-Giemsa staining. ×400.](cro-0010-1013-g01){#F1}

![Histopathological images and cell surface antigen analysis of bone marrow. **a** Histopathological image of the specimen. Atypical cells are confirmed (red arrow). May-Giemsa staining. ×1, 000. **b** Histopathological image of the specimen. Hemophagocytosis is confirmed. May-Giemsa staining. ×1, 000. **c** Cell surface antigen analysis of bone marrow cells. Analysis reveals strong deviation among cell surface of immunoglobulin light chain in B-lymphocyte fraction. Furthermore, the rate of CD20-positive cells is high, about 70%. CD, cluster of differentiation.](cro-0010-1013-g02){#F2}

![Clinical course of the patient. After diagnosis of diffuse large B-cell lymphoma, 375 mg/m^2^ rituximab therapy, once per week, was started on day 46 of hospitalization. Afterwards, pleural effusion and the values of LDH and sIL-2R markedly decreased, and the patient was discharged on day 109 of hospitalization. LDH, lactate dehydrogenase; sIL-2R, soluble interleukin-2 receptor.](cro-0010-1013-g03){#F3}

###### 

Reported cases of primary effusion lymphoma-like lymphoma including our case

  Case   Age, years   Sex   Symptoms                                                  HBV   HCV   HIV   EBV   HHV-8   HTLV-1   Serum LDH, U/L   Serum sIL-2R, U/mL   Pleural effusion   
  ------ ------------ ----- --------------------------------------------------------- ----- ----- ----- ----- ------- -------- ---------------- -------------------- ------------------ ----
  1      99           F     Hypoxemia                                                 ND    −     −     −     −       ND       169              ND                   \+                 \+
  2      52           F     ND                                                        ND    ND    −     −     ND      ND       ND               ND                   \+                 \+
  3      90           F     Orthopnea                                                 −     −     −     −     −       −        738              1,370                \+                 \+
  4      32           F     Abdominal distension, night sweats                        −     \+    −     −     −       −        2,344            7,090                \+                 −
  5      74           F     Dyspnea, edema of lower limbs                             −     \+    −     −     −       ND       574              14,000               \+                 \+
  6      88           M     Dyspnea, weakness                                         −     −     −     −     −       ND       670              ND                   \+                 ND
  7      68           M     Dyspnea                                                   ND    −     −     −     −       ND       230              ND                   \+                 \+
  8      77           M     Dyspnea, edema of lower limbs                             \+    −     −     \+    −       −        ND               ND                   \+                 \+
  9      79           M     Dyspnea                                                   −     −     \-    −     ND      ND       114              ND                   \+                 \+
  10     65           F     Cough, general fatigue, shortness of breath               −     −     ND    −     −       ND       ND               ND                   \+                 \+
  11     76           M     Cough, general fatigue, night sweats                      ND    −     −     −     −       −        377              525                  \+                 \+
  12     77           M     Abdominal distension, pitting edema of both lower limbs   −     −     −     −     −       ND       393              ND                   \+                 ND
  13     71           F     Abdominal distension                                      −     −     −     \+    −       ND       1,404            1,060                \+                 \+
  Our                                                                                                                                                                                   
  case   93           F     Hypotension, disturbance of consciousness                 0     ND    0     ND    ND      ND       286              1,700                \+                 −

"+" indicates that the data are positive or detected. "−" indicates that the data are negative or undetected. ND, not done or not described; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; HHV, human herpesvirus; HTLV, human T-cell leukemia virus; LDH, lactate dehydrogenase; sIL-2R, soluble interleukin-2 receptor.

###### 

Reported cases of primary effusion lymphoma-like lymphoma including our case (continued from Table [1](#T1){ref-type="table"})

  Case   Bone marrow infiltration   Immunohistochemistry                                    Chromosomal abnormality   Site involved                        Treatment                                                Outcome            Ref.
  ------ -------------------------- ------------------------------------------------------- ------------------------- ------------------------------------ -------------------------------------------------------- ------------------ ------
  1      −                          CD5, CD19, CD20, CD25, SmIgM, SmIgD, Ig-λ light chain   \+                        Pleura, pericardium                  Drainage                                                 Alive, 16 months   3
  2      −                          CD19, CD20, CD22, CD45, DR antigen                      \+                        Pleura, pericardium                  Unknown                                                  Unknown            12
  3      −                          CD20, CD79a, bcl-2                                      \+                        Pleura, epicardium, peritoneum       None                                                     Died, 5 months     13
  4      −                          CD10, CD19, CD20, HLA-DR                                \+                        Pleura, peritoneum                   THP--COP, PBSCT                                          Died, 22 months    14
  5      −                          CD19, CD20, CD25, CD45, HLA--DR, SmIgG-κ                \+                        Pleura, pericardium, peritoneum      THP--COP, rituximab                                      Alive, 26 months   15
  6      −                          CD20, CD30, CD45, CD79a                                 ND                        Pleura, pericardium                  R--CHOP                                                  Alive, 9 months    16
  7      −                          CD20, CD79a                                             −                         Pleura                               Pleural drainage, R-CHOP                                 Alive, 22 months   17
  8      −                          CD19, CD20, CD38, CD66, CD71, cCD79a                    \+                        Pleura                               Rituximab, cyclophosphamide, vincristine, prednisolone   Alive, 3 months    18
  9      −                          CD20, CD45, CD79a, bcl-2, bcl-6, MUM1                   \+                        Pleura                               Drainage, pleurodesis                                    Alive, 55 months   19
  10     −                          CD19, CD20, CD38, CD79a, CD138, MUM-1, PAX-5            −                         Pleura                               Rituximab, cyclophosphamide, vincristine, prednisolone   Died, 5.5 months   20
  11     −                          CD19, CD20, CD30, CD79a, Ig-λ light chain               \+                        Pleura                               R--CHOP                                                  Alive, 18 months   21
  12     −                          CD20, CD45, MUM-1                                       −                         Pleura, peritoneum                   R--CHOP                                                  Alive, 15 months   22
  13     −                          CD10, CD20, CD45, CD79a, bcl-6                          \+                        Pleura, peritoneum                   R--CHOP                                                  Died, 16 months    23
  Our                                                                                                                                                                                                                                  
  case   \+                         CD19, CD20, CD25, Ig-λ light chain                      −                         Bone marrow (pleura? pericardium?)   Rituximab                                                Alive, 28 months   

"+" indicates that the data are positive or detected. "−" indicates that the data are negative or undetected. ND, not done or not described; CD, cluster of differentiation; DR, D-related; HLA, human leukocyte antigen; MUM, multiple myeloma oncogene; PAX, paired box; EMA, epithelial membrane antigen; THP-COP, pirarubicin/cyclophosphamide/vincristine/prednisolone; PBSCT, peripheral blood stem cell transplantation; R-CHOP, rituximab-cyclophosphamide/doxorubicin/vincristine/prednisone.
